|GOLDEN JUBILEE LECTURE
|Year : 2003 | Volume
| Issue : 1 | Page : 17-23
Randomised clinical trials of choroidal melanoma treatment.
Bradley R Straatsma
Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095-7000, USA
Bradley R Straatsma
Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095-7000
Source of Support: None, Conflict of Interest: None
Purpose: To illustrate an approach to evidence-based medical practice by reporting the Collaborative Ocular Melanoma Study (COMS) randomised clinical trials and cohort studies of choroidal melanoma.
Methods: COMS randomised clinical trials of Iodine-125 (I-125) brachytherapy, adjunctive cohort study of visual acuity in eyes treated with brachytherapy and adjunctive natural history study. COMS randomised clinical trial of pre-enucleation radiation.
Results: The COMS I-125 brachytherapy trial (N = 1,317 patients) of medium-sized choroidal melanoma showed 5-year all-cause mortality of 18% [95% Confidence Interval (CI), 16-20%] and no statistically significant difference in mortality following 1-125 brachytherapy or enucleation. Adjunctive cohort natural history study (N-42 patients) of patients eligible for the I-125 brachytherapy trial who deferred treatment or had no melanoma treatment had a 5-year all-cause mortality of 30% (95% CI, 18-47%). The COMS pre-enucleation radiation trial (N = 1,003 patients) of large-sized choroidal melanoma showed 5-year all-cause mortality of 40% (95% CI, 37-44%).
Conclusions: Evidence derived from randomised clinical trials and cohort studies shows the need for longterm (ž 5 years) follow-up to determine the efficacy of treatment for choroidal melanoma by any modality. The rather similar 5-year mortality for treated and untreated medium melanoma patients suggests that metastatic dissemination may occur at an early stage of choroidal melanoma. To increase longterm survival, ocular treatment of choroidal melanoma must strive for diagnosis and treatment of melanoma at an early stage when metastasis is less likely and be combined with measures to detect and treat micrometastasis
Keywords: Melanoma, choroid, evidence, clinical trial, brachytherapy, cohort study
|How to cite this article:|
Straatsma BR. Randomised clinical trials of choroidal melanoma treatment. Indian J Ophthalmol 2003;51:17-23
|How to cite this URL:|
Straatsma BR. Randomised clinical trials of choroidal melanoma treatment. Indian J Ophthalmol [serial online] 2003 [cited 2020 Aug 8];51:17-23. Available from: http://www.ijo.in/text.asp?2003/51/1/17/14742
Celebrating 50 years of publication as the official journal of the All India Ophthalmological Society, the Indian Journal of Ophthalmology warrants all commendation and applause. For half a century, the Indian Journal of Ophthalmology has received the clinical observations, creative thoughts and original ideas of ophthalmic scientists, nurtured these contributions through scholarly peer review, and archived these scientific products through publication and worldwide distribution.
Led by a succession of distinguished editors [Table - 1], the Indian Journal of Ophthalmology has particular relevance to the populations of India, the geographic diversity of this large region and the clinical challenge presented to ophthalmologists by a population of more than one billion people. More broadly, the Journal is an important part of the mosaic of scientific journals published throughout the globe.
To translate the avalanche of new information from clinical research to clinical practice, ophthalmologists need to apply the principles of evidence-based medicine and ask three questions: (1) Are the results of the study valid? (2) What are the results? (3) Do these results help me in caring for my patients?,,,,
To answer these questions, it is important to understand the strengths and limitations of scientific study design and methodology. Case reports, for example, and consecutive case series may provide important insights regarding disease processes, describe new surgical procedures or generate hypotheses. Case series, however, describe clinical experiences and, with rare exceptions, do not produce scientific evidence. Case-control studies select people on the basis of the disease presence (cases) or disease absence (controls) and may be practice-based or population-based. Case-control studies are useful for rare diseases and may identify hypotheses, but cannot measure relative risk or disease incidence.
Providing evidence, cohort studies are prospective, longitudinal studies that select people on the basis of disease presence or disease absence, measure characteristics at the onset and follow participants periodically to monitor outcome. Because these studies are prospective and carried out over a period of time, cohort studies measure the incidence of disease or other outcome as well as relative risk. One type of cohort study is the natural history study in which people with the disease are followed to determine longterm outcome and risk factors.
Providing the highest level of experimental evidence, randomised clinical trials generally select people with specific disease characteristics, randomly assign the participants to various treatment options, minimise bias by masking the observers, and measure outcome. A clinical trial may be appropriate when (1) the disease to be studied is a substantial public health concern, (2) preliminary evidence exists that a "new" test treatment may be superior to the "standard" treatment, (3) a valid trial outcome may be obtained in a reasonable time, and (4) ethical patient safeguards are in place.,
The Collaborative Ocular Melanoma Study (COMS; [Table - 2], in progress since 1985 at 43 clinical centers in the United States and Canada illustrates use of the randomised clinical trial, cohort study and case series to build an evidence-based programme of choroidal melanoma management.
The COMS randomised trial of Iodine-125 (I-125) brachytherapy for choroidal melanoma screened 8,712 choroidal melanoma patients; 5,046 had melanoma of eligible size; 2,882 fulfilled all eligibility criteria, and 1,317 enrolled in the trial.,, Enrolled patients had medium-sized choroidal melanoma (2.5 mm to 10 mm in apical height, no more than 16 mm in longest basal diameter, and with exceptions, proximal border 2 mm or more from the optic disc border). Eligible patients were adults, free of detectable melanoma metastasis and with no history of other primary cancer.
Approximately half (1,371; 46% of 2,882) of the eligible patients were enrolled. Baseline demographic characteristics and tumour characteristics of enrolled and not-enrolled patients were well balanced for all factors important in determining outcome. Consequently, results of enrolled patients may be generalised to include eligible but not-enrolled patients.
To determine whether the enrolled patients are broadly representative of patients who would be candidates for treatment with I-125 brachytherapy, it was estimated that the 8,718 patients screened at COMS centers comprised 34-45% of all new cases of choroidal melanoma that occurred in the United States and Canada during the 11.5 years of COMS patient accrual. Based on the high proportion of melanoma cases screened at COMS Centers, it is reasonable to conclude that results of the COMS randomised trial of I-125 brachytherapy are generalisable to future patients who meet COMS eligibility criteria.
In the randomised trial of I-125 brachytherapy, 1,317 patients were enrolled; 660 were assigned randomly to enucleation, and 657 to I-125 brachytherapy. When histopathology was reviewed centrally, 658 (99.7%) of 660 eyes had choroidal melanoma and two eyes had carcinoma metastatic to the choroid. The I-125 brachytherapy protocol prescribed a radiation dose of 85 Gray (GY) at the tumour apex. The protocol utilised standard gold plaques that provided a 2-3 mm margin of treatment beyond the tumour border [Figure - 1].
For a typical case [Figure - 2], the I-125 plaque placement procedure was performed under monitored local anaesthesia or general anaesthesia. A conjunctival peritomy was performed, sutures were looped around the rectus muscle insertions, the melanoma was localised by transillumination with ophthalmoscopy, and the sclera was marked to position the central meridian of the melanoma and identify the placement of each fixation suture. With the plaque in place and slipknots on fixation sutures, plaque placement was confirmed by intraoperative ultrasonography to ensure a 3 mm margin of treatment beyond the tumour at 90 intervals around the circumference of the melanoma [Figure - 3]. After confirmation of precise plaque placement, fixation sutures were tied and conjunctiva was repositioned to the limbus.
Based on date of enrollment, 1,072 (81%) of the patients had been followed after treatment for 5 years and 416 (32%) for 10 years. The unadjusted estimated 5-year mortality rates were 19% for enucleation and 18% for brachytherapy; there was no statistically significant difference in mortality rates (P = 0.48). For 1,317 patients in the I-125 brachytherapy trial, the Kaplan-Meier estimate of 5-year all-cause mortality was approximately 18% [95% Confidence Interval (CI), 16-20%].
As an adjunct to the I-125 brachytherapy trial, a prospective non-randomised multicentre cohort study evaluated visual acuity in 623 eyes treated with I-125 brachytherapy and followed for at least one year. At baseline, before treatment, median visual acuity in the eye with melanoma was 6/9; 70% of eyes had 6/12 or better, and 10% of eyes had 6/60 or worse. Three years after I-125 brachytherapy, median visual acuity was 6/36; 34% of eyes had 6/12 or better and 45% of eyes had 6/60 or worse; the latter included eyes that were enucleated [Table - 3]. Life-table estimates of patients who lost six or more lines of visual acuity (a quadrupling of the minimum angle of resolution) from baseline were 18% by one year, 34% by two years, and 49% by three years after treatment. Overall, about half of treated eyes had substantial impairment of visual acuity three years after I-125 brachytherapy, defined either by loss of six or more lines of visual acuity (49% of eyes) or 6/60 or worse best-corrected visual acuity (45% of eyes).
Impairment of visual acuity after brachytherapy is shown in an eye with juxtafoveal melanoma and baseline visual acuity of 6/30 [Figure - 4]a. Two years following brachytherapy, the tumour had decreased in thickness, small retinal and choroidal blood vessels were obliterated in the area corresponding to the plaque and visual acuity was 6/120 [Figure - 4]b.
More extensive postradiation vascular alterations appear in an eye with juxtapapillary choroidal melanoma and visual acuity of 6/6 prior to brachytherapy [Figure - 5]a. Four years after brachytherapy, the tumour had decreased in thickness, chorioretinal degeneration surrounded the tumour, optic nerve pallor was present and visual acuity was counting Fingers at 3 feet [Figure - 5]b. Angiography showed obliteration of small, medium and large blood vessels in the retina and choroid, as well as remodeling of the remaining large vessels [Figure - 5]c.
As a further adjunct to the I-125 brachytherapy trial, a natural history study was performed as a prospective non-randomised multicentre cohort study. The natural history study evaluated mortality in patients who were eligible for the I-125 brachytherapy trial but chose to defer treatment or receive no melanoma treatment. Forty-two patients with medium-sized choroidal melanoma (42 eyes) chose to defer or receive no melanoma treatment and were followed for a median of 5.3 years (range, 4 - 10.7 years). Twenty-two (52%) of the 42 patients who declined treatment initially received subsequent melanoma treatment and 20 (48%) of the 42 patients had no melanoma treatment.
For the 42 melanoma patients who deferred or had no melanoma treatment, vital status was known at five and ten years for 32 and 20 patients, respectively; the Kaplan-Meier estimate of 5-year all-cause mortality was approximately 30% (95% CI, 18-47%; [Figure - 6]). This was greater than the I-125 brachytherapy trial 5-year all-cause mortality of 18% (95% CI, 16-20%), but the difference was not statistically significant [Figure - 7]. After adjusting for patient age and melanoma longest basal diameter, the 5-year risk of death for the 42 patients who deferred or had no treatment versus the I-125 brachytherapy patients was 1.54 (95% CI, 0.93 to 2.56). In aggregate, the patients who deferred or had no treatment had a 12% greater 5-year mortality and an approximately 50% greater risk of death, which is a probative but not conclusive evidence of a beneficial effect of medium-sized melanoma treatment.
Overlapping 95% Confidence Intervals may have stemmed from the discrepant sample size. The relatively small sample size of 42 patients who deferred or had no treatment results in reduced power to detect a statistically significant difference between 18% and 30% (a difference of 12%) was only 44%, but there was an 80% power to detect a difference of 20% or more.
Taken together, the greater mortality and higher relative risk of death among patients who deferred or had no treatment are evidence that tends to prove the beneficial life-extending effect of melanoma treatment. Although the evidence is probative and not conclusive, it forms a reasonable basis for recommending ocular treatment of medium-sized melanoma. However, the similarity of 5-year outcome emphasises the need for longterm follow-up (ž 5 years) to determine the efficacy of melanoma treatment by any means.
The rather similar 5-year mortality for treated and not treated medium-sized choroidal melanoma and calculations of tumour doubling time suggest that metastatic dissemination may occur at an early stage of choroidal melanoma.,,,, If metastasis has occurred, ocular treatment will control the tumour in the eye but have no effect on the growth of metastatic tumours or longterm survival.
Comparison between 5-year mortality of treated and not treated medium melanoma patients is important in understanding the natural history of choroidal melanoma, but the goal of choroidal melanoma therapy is the maintenance of normal life expectancy. Therefore, based on uncertain time of tumour metastasis and observed differences in 5-year mortality in COMS reports of small sized, medium,, and large choroidal melanoma, [Table - 4], as well as many other studies,,, every effort should be made to achieve accurate diagnosis and treatment of choroidal melanoma at small size. In addition, to increase longterm survival, ocular treatment of choroidal melanoma must be combined with measures to detect and treat micrometastasis.
In summary, this Golden Jubilee Lecture celebrates the Indian Journal of Ophthalmology as the peer reviewed scientific voice of the All India Ophthalmological Society and emphasises the growing importance of evidence-based medicine as the basis for clinical practice. To illustrate evidence-based research, COMS randomised clinical trials and cohort studies were described. The COMS randomised trial of I-125 brachytherapy for medium-sized choroidal melanoma demonstrated a 5-year all-cause mortality of 18% (95% CI, 16-20%) and no significant difference in mortality after treatment with I-125 brachytherapy or enucleation. An adjunctive cohort study of 623 eyes treated with radiation showed that approximately 50% of treated eyes had a substantial loss of visual acuity (six lines or more of acuity or visual acuity of 6/60 or less) three years after brachytherapy. A cohort natural history study of 42 patients who were eligible for the I-125 brachytherapy trial but chose to defer treatment or receive no treatment, had a 5-year all-cause mortality of 30% (95% CI, 18-47%). The greater mortality and approximately 50% higher 5-year death rate among patients who deferred melanoma or had no choroidal melanoma treatment are probative but not conclusive evidence of a life-extending benefit of treatment for medium choroidal melanoma. To increase long term survival, choroidal melanoma should be diagnosed and treated at an early stage when there is less likelihood of metastasis and ophthalmologists must strive to combine ocular treatment with measures to detect and treat micrometastatic disease.
As the quest for evidence-based medical practice advances, the Indian Journal of Ophthalmology has particular relevance to the populations, cultures and geographic variations of India as well as far reaching relevance to ophthalmic practice worldwide.
| References|| |
Oxman AD, Sackett DL, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature I. How to get started. The Evidence-Based Medicine Working Group. JAMA
Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature II. How to use an article about therapy or prevention A. Are the results of the study valid? JAMA
Jaeschke R, Guyatt GH, Sackett DL, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA
Coleman AL. Applying evidence-based medicine in ophthalmic practice. (Editorial): Am J Ophthalmol
Cruickshanks KJ. Epidemiology and health outcomes. In: Albert DM, editors. A Physician's Guide to Health Care Management.
New York: Blackwell Science Inc
Bressler SB, Bressler NM. Randomized clinical trials in ophthalmology in 2001: Twenty-fifth anniversary of the first publication from the Diabetic Retinopathy Study. Am J Ophthalmol
Bressler SB, Diener-West M, Taylor HR, Staatsma BR. Clinical trials digest on the Internet At AJO. COM: Entering a new information age. Am J Ophthalmol
Collaborative Ocular Melanoma Study Group. The COMS randomised trial of Iodine-125 brachytherapy for choroidal melanoma, II. Characteristics of patients enrolled and not enrolled: COMS Report No.17. Arch Ophthalmol
Collaborative Ocular Melanoma Study Group. The COMS randomised trial of Iodine-125 brachytherapy for choroidal melanoma, III. Initial mortality findings: COMS Report No.18. Arch Ophthalmol
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of Iodine 125 brachytherapy for medium choroidal melanoma, I: Visual acuity after 3 years: COMS Report No.16. Ophthalmology
Straatsma BR, Diener-West M, Caldwell R, Engstrom RE, for the Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol
Laquis SJ, Fleming JC, Wilson MW, Haik BG. A rapidly growing choroidal melanoma. Am J Ophthalmol
Friberg TR, Fineberg E, McQuaig S. Extremely rapid growth of a primary choroidal melanoma. Arch Ophthalmol
Manschot WA. The natural history of uveal melanomas and its therapeutic consequences. Doc Ophthalmol
Collaborative Ocular Melanoma Study Group. The collaborative ocular melanoma study (COMS) randomised trial of pre-enucleation radiation of large choroidal melanoma II: Initial mortality findings: COMS Report No.10. Am J Ophthalmol
Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling time in metastatic malignant melanoma of the uvea. Ophthalmology
Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma: COMS Report No.4. Arch Ophthalmol
Collaborative Ocular Melanoma Study Group. The collaborative ocular melanoma study (COMS) randomised trial of pre-enucleation radiation of large choroidal melanoma I: Characteristics of patients enrolled and not enrolled: COMS Report No.9. Am J Ophthalmol
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma: II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol
Coleman K, Baak JPA, Van Dienst P, Mullaney J, Farrell M, Fenton M. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol
[Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4], [Figure - 5], [Figure - 6], [Figure - 7]
[Table - 1], [Table - 2], [Table - 3], [Table - 4]